Followers | 261 |
Posts | 51308 |
Boards Moderated | 17 |
Alias Born | 08/29/2007 |
![](https://investorshub.advfn.com/uicon/108458.png?cb=1482855649)
Sunday, July 23, 2023 4:40:34 PM
GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Twist Bioscience Corporation is a synthetic biology company. The Company has developed a disruptive DNA synthesis platform. The core of its platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for sample preparation and antibody libraries for drug discovery and development. The Company's product lines, synthetic biology tools and NGS tools, addresses different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.
![](http://investorshub.advfn.com/uimage/uploads/2023/7/23/mxozcIMG_0631.gif)
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent TWST News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 07:19:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:05:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 01:57:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 07:31:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 07:24:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 07:20:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 07:18:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 07:15:45 PM
- Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor • Business Wire • 06/06/2024 12:00:00 PM
- Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety • Business Wire • 06/04/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 04:22:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 07:20:44 PM
- Twist Bioscience to Present at Upcoming Investor Conferences • Business Wire • 05/23/2024 12:00:00 PM
- Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications • Business Wire • 05/13/2024 12:00:00 PM
- Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 05/08/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:05:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:05:24 PM
- Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results • Business Wire • 05/02/2024 08:05:00 PM
- Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024 • Business Wire • 04/18/2024 12:00:00 PM
- Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations • Business Wire • 03/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:36 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM